BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. …
Tag: biotech
I bought Antares @ $3.95, I see a move to $4.35 short term
I bought Antares @ $3.95, I see a move to $4.35 short term. I think from tomorrow to beginning of next week, we see the move. From above, we can clearly see a tightening wedge forming in the chart. I…
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Today, we will take a detailed look into a company that has an imminent catalyst, a number of important Phase II and Phase III data releases throughout 2013, and a product pipeline with potential to tap into a $17B market.…
Approaching Biopharma Catalyst Events
Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks I list…
Cleveland BioLabs Offers Medical Countermeasures Against Potential Terrorist Attacks.
Sadly, terrorism is a real threat to the United States homeland as we just saw last week. However, we can take a little solace in the fact that the recent terrorist attack involved crude homemade non-radiological bombs. The fact remains…
Weekend update with some charts, Market forecast and opinion. (VIDEO)
Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
The advent of The Affordable Care Act (Obamacare) is on the horizon as the healthcare sector of the market continues its strong rally. With new Food and Drug Administration (FDA) regulatory easing, congressional bills, and The Obama Administration directive in…
AVEO Pharma’s Tivozanib Likely To Be Approved
With the current record market run, small cap biopharmas have kept pace and continue to trend higher, being one of the best sectors for both trading and investing over the past year. With 39 new drugs approved, 2012 showed the…
